EdgeMarket › What Silverarc Capital Management, Llc reported owning
What Silverarc Capital Management, Llc reported owning
As filed on Form 13F for the quarter ending 2026-03-31, up to 45 days after that date. Long-only US-listed equity — shorts, bonds, cash and non-US listings are not on the form, so this is one leg of the book, not the book.
Reported value
979.8MPositions
73Quarter
2026-03-31Shown below
50largest by value
| holding | value | % of book | shares | price | 1y |
|---|---|---|---|---|---|
| unmapped CUSIP 483497103 | 57.9M | 5.9% | 2.9M | — | — |
| DNTH Dianthus Therapeutics, Inc. /DE/ | 54.9M | 5.6% | 654.7K | 111.10 | +374.4% |
| COGT Cogent Biosciences, Inc. | 50.6M | 5.2% | 1.3M | 36.73 | +209.6% |
| CELC Celcuity Inc. | 40.9M | 4.2% | 357.9K | 93.53 | +91.8% |
| IMNM Immunome Inc. | 40.5M | 4.1% | 1.9M | 28.52 | +198.0% |
| KOD Kodiak Sciences Inc. | 37.8M | 3.9% | 991.9K | 38.33 | +303.5% |
| unmapped CUSIP 670703107 | 36.4M | 3.7% | 354.9K | — | — |
| ABVX Abivax S.A. | 33.7M | 3.4% | 302.5K | 114.95 | +59.9% |
| GLUE Monte Rosa Therapeutics, Inc. | 32.9M | 3.4% | 2.0M | 14.30 | +222.8% |
| ERAS Erasca, Inc. | 30.0M | 3.1% | 1.9M | 17.63 | +1107.5% |
| ASND Ascendis Pharma A/S | 28.5M | 2.9% | 124.7K | 253.29 | +31.4% |
| URGN UroGen Pharma Ltd. | 27.0M | 2.8% | 1.5M | 46.86 | +142.7% |
| RYTM RHYTHM PHARMACEUTICALS, INC. | 26.6M | 2.7% | 306.0K | 110.00 | +11.4% |
| PRAX Praxis Precision Medicines, Inc. | 23.1M | 2.4% | 71.6K | 375.94 | +730.8% |
| ZBIO Zenas BioPharma, Inc. | 22.2M | 2.3% | 1.1M | 32.29 | +97.9% |
| SNDX Syndax Pharmaceuticals Inc | 20.8M | 2.1% | 889.0K | 19.65 | +24.8% |
| unmapped CUSIP 152309100 | 18.5M | 1.9% | 466.3K | — | — |
| SRRK Scholar Rock Holding Corp | 16.7M | 1.7% | 339.6K | 56.50 | +64.2% |
| ALKS Alkermes plc. | 16.3M | 1.7% | 460.3K | 48.33 | +66.8% |
| ORIC Oric Pharmaceuticals, Inc. | 13.9M | 1.4% | 1.1M | 14.20 | +49.3% |
| IRON Disc Medicine, Inc. | 12.5M | 1.3% | 196.0K | 79.81 | +35.9% |
| HLXC Helix Acquisition Corp. III | 12.3M | 1.3% | 1.2M | 10.93 | — |
| XENE Xenon Pharmaceuticals Inc. | 11.5M | 1.2% | 197.8K | 60.77 | +61.5% |
| CGON CG Oncology, Inc. | 11.3M | 1.1% | 166.3K | 79.81 | +212.6% |
| IMVT Immunovant, Inc. | 10.3M | 1.1% | 414.2K | 44.37 | +199.4% |
| SYRE Spyre Therapeutics, Inc. | 9.4M | 1.0% | 186.6K | 106.49 | +551.3% |
| BIIB BIOGEN INC. | 9.3M | 1.0% | 51.0K | 216.78 | +56.0% |
| GH Guardant Health, Inc. | 9.1M | 0.9% | 98.5K | 170.69 | +191.8% |
| PCVX Vaxcyte, Inc. | 8.4M | 0.9% | 145.0K | 62.62 | +100.3% |
| SVRA Savara Inc | 7.8M | 0.8% | 1.4M | 5.59 | +80.9% |
| BNTC Benitec Biopharma Inc. | 7.6M | 0.8% | 717.7K | 13.48 | +4.7% |
| ORKA Oruka Therapeutics, Inc. | 7.4M | 0.8% | 150.9K | 107.96 | +649.7% |
| CGEN COMPUGEN LTD | 7.1M | 0.7% | 3.3M | 2.62 | +81.6% |
| TRVI Trevi Therapeutics, Inc. | 6.1M | 0.6% | 511.1K | 17.96 | +142.0% |
| INSM INSMED Inc | 5.9M | 0.6% | 35.9K | 125.77 | -2.8% |
| VCYT VERACYTE, INC. | 5.8M | 0.6% | 179.7K | 42.31 | +43.5% |
| CERS CERUS CORP | 5.8M | 0.6% | 3.2M | 2.81 | +142.2% |
| CLDX Celldex Therapeutics, Inc. | 5.7M | 0.6% | 178.4K | 40.38 | +93.3% |
| CCCC C4 Therapeutics, Inc. | 5.0M | 0.5% | 1.9M | 4.00 | +53.8% |
| CYTK CYTOKINETICS INC | 4.7M | 0.5% | 71.2K | 76.84 | +105.9% |
| CLYM Climb Bio, Inc. | 4.7M | 0.5% | 684.9K | 17.28 | +668.0% |
| CMPX Compass Therapeutics, Inc. | 4.5M | 0.5% | 859.0K | 2.40 | -13.7% |
| SRZN Surrozen, Inc./DE | 4.2M | 0.4% | 144.3K | 23.99 | +108.6% |
| CTNM Contineum Therapeutics, Inc. | 3.9M | 0.4% | 301.7K | 17.19 | +93.8% |
| ZURA Zura Bio Ltd | 3.3M | 0.3% | 560.7K | 5.85 | +234.3% |
| FULC Fulcrum Therapeutics, Inc. | 3.2M | 0.3% | 419.9K | 3.83 | -41.7% |
| ABEO ABEONA THERAPEUTICS INC. | 2.9M | 0.3% | 648.9K | 6.09 | -13.0% |
| CAMP Camp4 Therapeutics Corp | 2.9M | 0.3% | 653.6K | 4.48 | +190.9% |
| ANNX Annexon, Inc. | 2.8M | 0.3% | 496.5K | 5.07 | +136.9% |
| ELUT ELUTIA INC. | 2.6M | 0.3% | 2.5M | 0.95 | -55.1% |
A position that grew quarter on quarter may simply reflect a higher price: if the stock rose 40% and the manager did nothing, the reported value rose 40%. Reading that as accumulation is reading the price back to yourself. More on that →
The whole archive is one click away.
Screener, filings, insider flow, backtests and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →